Lu Daopei Hospital
China's largest specialist hematology hospital network for bone marrow transplantation and CAR-T cell therapy, founded by the late Academician Lu Daopei and now treating patients with relapsed and refractory blood cancers from Pakistan, Canada, Norway, the Middle East and beyond across its Beijing and Hebei Yanda campuses.
About Lu Daopei Hospital
Lu Daopei Hospital is one of China's leading specialist hematology hospital networks, founded in 2001 in Beijing by the late Professor Lu Daopei (1931 to 2025), an Academician of the Chinese Academy of Engineering and the pioneer of bone marrow transplantation in China and Asia. Professor Lu performed Asia's first bone marrow transplant in 1964 and established the Peking University Institute of Hematology in 1981 before founding Beijing Daopei Hospital twenty years later. Today the Lu Daopei Medical Group operates multiple campuses, with the two principal hospitals being Beijing Lu Daopei Hospital in the Yizhuang Economic and Technological Development Zone (27,000 m², 300 beds, 36 air laminar flow transplant rooms) and Hebei Yanda Lu Daopei Hospital in Yanjiao (36,590 m², 490 beds, 51 air laminar flow rooms, with over 700 staff). The group is medically led by Dr. Peihua (Peggy) Lu, daughter of the founder, US-trained at Nebraska and Stanford.
Lu Daopei is the largest dedicated hematology hospital network in China, focused entirely on blood disorders and blood cancers. The group offers a full spectrum of treatment for leukemia (B-ALL, T-ALL, AML), lymphoma, multiple myeloma, myelodysplastic syndromes, aplastic anemia, transfusion-dependent thalassemia and sickle cell disease. By the end of 2022 the group had completed 7,852 hematopoietic stem cell transplants, of which 5,597 (71.9%) were haploidentical, placing Lu Daopei among the largest BMT programmes in the world. Its CAR-T cell therapy programme is equally substantial, with more than 2,110 patients enrolled in CAR-T clinical trials by end-2023 and an approximate complete remission rate of 90% in eligible patients with relapsed or refractory B-cell acute lymphoblastic leukemia, B-cell lymphoma and multiple myeloma. The group is recognised for pioneering CAR-T to allo-HSCT bridging protocols, CD123 CAR-T for AML, and CD7 NS7CAR-T for T-cell malignancies.
Beijing Lu Daopei Hospital is a GCP-certified clinical trial institution, registered with China's National Medical Products Administration. Hebei Yanda Lu Daopei Hospital was awarded the AAA Credit Evaluation and Five-Star Hospital ratings by the Chinese Association of Non-Public Medical Institutions in 2019, and the group's Synarc specialty hematology laboratory has passed CAP (College of American Pathologists) certification. Lu Daopei's research team has presented over 150 times at top international hematology meetings since 2018, including ASH, EHA, EBMT and JSH, and published more than 300 academic papers. The group is backed by Investcorp's China Pre-IPO Healthcare Fund and, in 2026, partnered with Florence Nightingale Hospital Group in Turkey to launch the MENA region's first dedicated CAR-T stem cell therapy centre. The International Regenerative Medicine Foundation has previously honoured Lu Daopei with a Stem Cell and Regenerative Medicine Action Award.
CancerFax works directly with Lu Daopei's International Centre to help patients from outside China access the group's hematology and cellular therapy programmes. From sharing your records and pathology slides for preliminary clinical evaluation, to securing the right BMT or CAR-T pathway, arranging Chinese Medical Visa support, accredited translation of your reports, and planning the longer stay required for transplant or CAR-T care, CancerFax coordinates the entire journey at no charge to the patient. For families navigating relapsed or refractory leukemia, lymphoma or myeloma, where decisions cannot wait, our role is to compress the path between diagnosis confusion and a clear, evidence-based answer from the Lu Daopei clinical team.
| Hospital at a Glance | |
|---|---|
| Country | China |
| Cities | Beijing (Daxing District) and Hebei Yanjiao |
| Established | 2001 (Beijing campus); group later expanded to Hebei Yanda and beyond |
| Hospital Type | Private Specialist Hematology Hospital Group (Lu Daopei Medical Group) |
| Accreditation | GCP-Certified Clinical Trial Institution (NMPA) · AAA Credit · Five-Star Hospital · CAP-certified Synarc Specialty Hematology Lab |
| Beds | Beijing: 300 (36 laminar flow rooms) · Hebei Yanda: 490 (51 laminar flow rooms) |
| Annual Patients | ⚠ VERIFY: ~67,000 outpatient and ~12,000 inpatient (Hebei figures from secondary sources) |
| Research Focus | HSCT (incl. haploidentical), CAR-T cell therapy, hematologic malignancies, CAR-T bridging to allo-HSCT, cellular immunotherapy |
Why Patients Choose Lu Daopei Hospital
Lu Daopei is built for patients with leukemia, lymphoma and myeloma — particularly relapsed or refractory cases where standard treatments have failed and bone marrow transplantation or CAR-T cell therapy is the next step.
Cancer Specialties and Clinical Departments
Lu Daopei is a fully specialist hematology hospital network with four core clinical departments (BMT, General Hematology, Lymphoma and Myeloma Center, and Pathology and Specialty Hematology Lab) supporting the full spectrum of blood cancers and blood disorders.
Advanced Treatment Capabilities
Key Specialists at Lu Daopei Hospital
Lu Daopei was founded by the late Professor Lu Daopei (1931 to 2025), Academician of the Chinese Academy of Engineering, recipient of the CIBMTR Distinguished Service Award in 2016, and architect of much of modern Chinese hematology, including the China BMT Registry, the China Marrow Donor Program and the country's first cord blood bank. The medical group is now led by his daughter and Medical President, Dr. Peihua (Peggy) Lu, M.D., who trained with Profs. James Armitage at the University of Nebraska and Stanley Schrier and Robert Negrin at Stanford before returning to China. Across the group the clinical team is organised into four core departments: Department of BMT, Department of General Hematology, Lymphoma and Myeloma Center, and Pathology and Specialty Hematology Lab.
Senior physicians include Dr. Xian Zhang (Clinical Professor, General Hematology), Dr. Junfang Yang (Clinical Associate Professor, General Hematology), Dr. Fanyong Lv (Clinical Associate Professor, General Hematology), and a wider team of haematologists, BMT physicians and lymphoma and myeloma specialists across the Beijing and Hebei Yanda campuses. ⚠ VERIFY: secondary sources cite approximately 106 transplantation physicians and 320 nursing staff across the group, but exact current figures should be confirmed with the International Centre. Patients seeking consultation with a specific physician or a second opinion may submit their request through CancerFax, which works with the Lu Daopei International Centre to match each case to the appropriate clinical lead before travel is confirmed.
Patients seeking specific physician consultations or second opinions may request a review through the CancerFax coordination process before confirming travel or admission.
Clinical Infrastructure and Treatment Technology
Lu Daopei's twin-campus infrastructure is purpose-built for high-volume haematology, transplantation and cellular immunotherapy, with dedicated CAR-T manufacturing, laminar-flow transplant wards, an accredited specialty haematology laboratory and a GCP-certified clinical trials platform.
- Apheresis suites and clean-room cell processing for autologous CAR-T cell therapy
- Active CAR-T constructs covering CD19, CD22, BCMA, CD123 and CD7 (NS7CAR-T), including dual-target and bridge-to-HSCT protocols
- ⚠ VERIFY: TIL and NK cell therapy capabilities referenced in secondary sources; current availability should be confirmed with the International Centre
- 36 air laminar flow transplant rooms at Beijing Lu Daopei Hospital plus 51 at Hebei Yanda for sterile HSCT care
- High-volume haploidentical, matched-related, matched-unrelated and cord blood transplant programmes (5,597 haploidentical HSCTs by end-2022)
- Integrated apheresis, cryopreservation and conditioning regimen management within each campus
- CAP-certified Synarc Pathology and Specialty Hematology Laboratory
- Comprehensive molecular diagnostics including NGS, flow cytometry, cytogenetics, FISH and minimal residual disease (MRD) monitoring
- HLA typing and donor matching for unrelated and haploidentical transplants
- GCP-certified Clinical Trial Institution (registered with the National Medical Products Administration, 2019)
- Active CAR-T clinical trials in B-ALL, B-cell lymphoma, multiple myeloma (BCMA), AML (CD123) and T-cell malignancies (CD7)
- Research collaborations with Tsinghua University Medical College and the Institute of Biophysics of the Chinese Academy of Sciences
International Patient Support at Lu Daopei Hospital
Lu Daopei runs a dedicated International Centre with a structured, fully documented patient pathway covering pre-arrival assessment, visa support, airport pickup, in-hospital coordination and post-treatment follow-up.
What to Prepare Before Traveling
- arrow_rightShare complete pathology reports, bone marrow biopsy results, flow cytometry, cytogenetics, MRD where available, HLA typing if previously done, prior chemotherapy and transplant history, and recent imaging in English with the International Centre at least one to two weeks before travel.
- arrow_rightApply for a Chinese Medical Visa (M category) at the Chinese embassy or consulate in your country; Lu Daopei's International Centre will provide the official hospital invitation letter for the patient and one or two accompanying family members.
- arrow_rightPlan for a longer stay than a typical hospital admission: standard BMT inpatient time is approximately 4 to 6 weeks, with at least six months recommended in Beijing or Yanjiao afterwards for post-transplant follow-up. CancerFax helps families plan accommodation and visa extensions for this full duration.
To reach Lu Daopei's International Centre directly, phone or WhatsApp +86 131 3160 9162, or email [email protected]. The group's English-facing site is ludaopei.com (the ludaopei.org domain may be used for the dedicated international portal). CancerFax coordinates all communication with the International Centre on your behalf, including pre-travel translation of your reports, and remains your single point of contact through admission, treatment and follow-up at no cost.
Patient Facilities and Accommodation at Lu Daopei Hospital
Lu Daopei's twin campuses combine high-volume hematology infrastructure with patient-centred accommodation, including dedicated laminar-flow transplant rooms, family-friendly inpatient rooms and a halal restaurant on the Hebei Yanda campus.
Family members travelling with international patients should plan for at least one accompanying companion to stay overnight in the inpatient room — one escort bed is provided in the patient room. Additional family members can stay in nearby hotels arranged by the International Centre, with several walking-distance and short-drive options around both the Yizhuang and Yanjiao campuses.
How to Reach Lu Daopei Hospital
Lu Daopei operates two main campuses near Beijing: the original Beijing Lu Daopei Hospital in Yizhuang (Daxing District) and the larger Hebei Yanda Lu Daopei Hospital in Yanjiao, both approximately 40 minutes by car from Beijing Capital International Airport.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Lu Daopei Hospital — Patient Questions Answered
CancerFax acts as your dedicated coordinator for the entire Lu Daopei journey. You begin by sharing your medical records, including pathology, bone marrow biopsy, flow cytometry, cytogenetics, MRD if available, prior chemotherapy and transplant history, and recent imaging through our secure intake. Our clinical team reviews your case and identifies the right Lu Daopei department for your diagnosis, whether that is the Department of BMT, the General Hematology Department, the Lymphoma and Myeloma Center, or the CAR-T Clinical Trial pathway. We then submit your case to Lu Daopei's International Centre and work with their team to obtain a formal written clinical evaluation.
Once a treatment plan is confirmed, CancerFax assembles your full pre-travel pack: itemised cost estimates from Lu Daopei with no CancerFax mark-up, Chinese Medical Visa invitation letters, accredited translation of your home-country reports, family accommodation guidance near the Yizhuang or Yanjiao campus, and detailed planning for the longer stay required for transplant or CAR-T care. We remain your single point of contact through admission, treatment and follow-up. There is no fee to the patient for any of this coordination.
Lu Daopei is a fully specialist hematology hospital network, with deep expertise in acute and chronic leukemias (B-ALL, T-ALL, AML, CML, CLL), Hodgkin and Non-Hodgkin lymphomas, multiple myeloma and other plasma cell disorders, myelodysplastic syndromes, myeloproliferative neoplasms, aplastic anemia, transfusion-dependent beta-thalassemia, sickle cell disease and certain hereditary immunodeficiency disorders. The group's two flagship areas are hematopoietic stem cell transplantation (7,852 HSCTs by end-2022, with a strong haploidentical programme) and CAR-T cell therapy (over 2,110 trial patients enrolled by end-2023). If you are unsure whether your specific diagnosis falls within Lu Daopei's scope, share your records through CancerFax and we will confirm departmental fit before any travel commitment.
Lu Daopei is one of the world's most experienced CAR-T centres by patient volume, with active clinical trials covering CD19 and CD22 CAR-T for B-cell ALL and B-cell lymphoma, BCMA CAR-T for multiple myeloma, CD123 CAR-T for acute myeloid leukemia, and CD7 NS7CAR-T for T-cell malignancies. The group also pioneered the practice of timely bridging from CAR-T into allogeneic HSCT to reduce relapse risk. Eligibility depends on diagnosis, prior treatment history, current disease status, age, performance status and several other clinical factors.
CancerFax submits your detailed records to the Lu Daopei clinical team to obtain a written eligibility opinion. If you are not currently a candidate, we will also help you understand alternative options including stem cell transplant or alternative cellular therapies elsewhere in China, so that your decision is based on what is genuinely possible for your case right now, not a generic information leaflet.
Yes. Lu Daopei's International Centre is set up around remote pre-assessment. The structured pathway begins with medical record collection by email or WhatsApp, followed by case discussion with the relevant hematology or BMT specialist, and culminates in an official written medical evaluation delivered to you by email along with an indicative financial estimate. The typical turnaround is one to two weeks, depending on the completeness of records submitted and the complexity of the case. CancerFax facilitates this end-to-end and follows up with the International Centre on your behalf so that you can make a fully informed decision before booking any flights, which is particularly important given that BMT and CAR-T journeys require a six-month minimum stay in China for follow-up.
Costs at Lu Daopei are typically substantially lower than at comparable hematology centres in North America, Europe, the Middle East or Australia, though the final amount depends heavily on diagnosis, donor type (matched related, matched unrelated or haploidentical for BMT), the specific CAR-T construct, length of admission, supportive care needs and post-transplant follow-up. Lu Daopei's International Centre provides a formal written cost estimate and official invoice as part of the pre-arrival pathway. Patients pay a deposit on admission, and the account is reconciled at discharge with refunds for any unused balance. Cash, bank transfer, Visa and MasterCard are accepted. CancerFax shares the estimate with you at no extra charge and with no CancerFax mark-up on hospital fees, and can also help you compare costs across other leading Chinese hematology and CAR-T centres if you are weighing multiple options.
Send Your Medical Reports to Lu Daopei Hospital via CancerFax
CancerFax reviews your records, identifies the right Lu Daopei department, and coordinates your BMT or CAR-T consultation in Beijing or Hebei Yanjiao, at no cost, with no obligation, and with full medical confidentiality throughout.